Posted by Michael Wonder on 16 Oct 2023
FDA approves neo-adjuvant/adjuvant pembrolizumab for resectable non-small cell lung cancer
16 October 2023 - Today, the FDA approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neo-adjuvant treatment, and with continuation of single-agent pembrolizumab as post-surgical adjuvant treatment for resectable (tumours ≥4 cm or node positive) non-small-cell lung cancer.
Efficacy was evaluated in KEYNOTE-671, a multi-centre, randomised, double-blind, placebo-controlled trial in 797 patients with previously untreated and resectable stage II, IIIA, or IIIB (N2) non-small-cell lung cancer by AJCC 8th edition.
